TOWA PHARMACEUTICAL CO.,LTD. (4553) Stock Price

Towa Pharmaceutical is primarily engaged in the manufacturing and sale of pharmaceutical products for medical use. The company particularly focuses on manufacturing generic drugs—pharmaceuticals with equivalent efficacy that are brought to market after the safety and effectiveness of original drugs have been confirmed.

Towa Pharmaceutical operates through two reporting segments: domestic and international. In Japan, the company sells manufactured pharmaceuticals directly to medical institutions through its own sales offices, as well as to distributors, pharmaceutical wholesalers, and other pharmaceutical manufacturers.

Jadolph Pharmaceutical engages in product sales and contract manufacturing with Towa Pharmaceutical and other pharmaceutical manufacturers. Daichi Kasei undertakes contract research and manufacturing of active pharmaceutical ingredients for Towa Pharmaceutical, while Green Caps Pharmaceutical handles soft capsule manufacturing.

Sansei Pharmaceutical plans, develops, and provides contract manufacturing services for health foods and pharmaceuticals. Through these operations, Towa Pharmaceutical maintains a diverse product portfolio and meets a wide range of customer needs.

In the international segment, Towa Pharma International Holdings, S.L. oversees the generic pharmaceutical business in Europe and North America. This holding company group operates research, development, and manufacturing facilities in Europe, and engages in generic pharmaceutical sales, contract research and development, and manufacturing.

Towa Pharmaceutical outsources research, development, and manufacturing to group companies under Towa Pharma International Holdings, thereby advancing its international business operations and strengthening its competitive position in global markets.

Towa Pharmaceutical is committed to contributing to people's health, primarily through generic pharmaceutical products. The company upholds the pledge "T-SMILE," prioritizing integrity, swift decision-making, and innovation to become a trusted enterprise in local communities. Building on its generic pharmaceutical business foundation, the company is expanding into new health-related ventures.

The company has formulated its medium-term management plan "PROACTIVE III" for 2024-2026 and is advancing its growth strategy based on three core principles. First, it is evolving its domestic generic pharmaceutical business by establishing stable supply systems and advancing supply chain sophistication. The company also emphasizes strengthening quality assurance and adapting to sustainable industry structures.

Second, it aims to establish a foundation for new markets and new businesses by expanding its overseas pharmaceutical operations. Specifically, it is strengthening its revenue base through new product launches in Western markets and targeting expansion to over 55 countries. In health-related businesses, the company contributes to realizing a healthy longevity society through participation in smart city initiatives and development of new pharmaceuticals.

Furthermore, the company is strengthening sustainability-focused management to support sustainable growth. It is working on reducing environmental impact and drug repositioning while improving workplace environments where employees find fulfillment. The company has established a human resources training center to support employee skill development and is actively recruiting diverse talent. Through these initiatives, Towa Pharmaceutical aims to achieve sustainable growth.